COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Randomized, Controlled Trial With Hybrid Fractional Laser

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03647189
Recruitment Status : Recruiting
First Posted : August 27, 2018
Last Update Posted : December 4, 2019
Information provided by (Responsible Party):

Brief Summary:
This randomized, controlled trial will evaluate hybrid fractional laser treatment for vulvovaginal atrophy in breast cancer survivors and menopausal females

Condition or disease Intervention/treatment Phase
Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia Device: Hybrid Fractional Laser Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Controlled Trial With Hybrid Fractional Laser for Vulvovaginal Atrophy in Breast Cancer Survivors and Menopausal Females
Actual Study Start Date : August 10, 2018
Estimated Primary Completion Date : January 30, 2020
Estimated Study Completion Date : January 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment Arm
Subjects will be treated with hybrid fractional laser
Device: Hybrid Fractional Laser
Hybrid Fractional Laser

Placebo Comparator: Control Arm Device: Hybrid Fractional Laser
Hybrid Fractional Laser

Primary Outcome Measures :
  1. Change from baseline in Vaginal health index score (VHIS) [ Time Frame: 6 months ]
    Scores vaginal health by scoring it from 1(none) - 5(excellent).

  2. Change from baseline in Female sexual function index questionnaire (FSFI) [ Time Frame: 6 months ]
    Scoring 0(minimum) - 5(maximum)

  3. Change from baseline in day-to-day impact of vaginal aging questionnaire [ Time Frame: 6 months ]

  4. Change from baseline in histology [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Change from baseline in photography [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Healthy biological female aged between 40 to 70 years 2. Is post-menopausal with a AND b OR c:

    1. No menses for at least 12 months
    2. Follicle-stimulating hormone (FSH) level over 40mlU/mL
    3. Has had a bilateral oophorectomy at least 12 months ago with no hormone replacement 3. Is experiencing at least two self-reported symptoms of GSM, such as
    1. Vaginal irritation in the absence of infection
    2. Chronic burning sensation
    3. Chronic itching in the absence of infection
    4. Recurring urinary tract infections (UTIs)
    5. Vaginal dryness during sexual activity
    6. Pain during sexual activity (dyspareunia) 4. Has been experiencing symptoms of GSM for greater than 3 months 5. Is unable due to a medical contraindication or unwilling to receive hormone-based vaginal therapy 6. Early menopause after breast cancer 7. Normal and up to date pap smear, if applicable 8. Is sexually active (i.e. intravaginal intercourse) or has the potential and desire to be sexually active if symptoms of GSM improve 9. Can read, understand and sign informed consent form 10. Has indicated willingness to participate in the study by signing an informed consent form 11. Agrees to adhere to the treatment and follow-up schedule and post treatment care instructions

Exclusion Criteria:

  • 1. Undiagnosed abnormal genital bleeding 2. Has history of pelvic surgery or other energy-based vaginal therapy within 12 months prior to enrollment 3. Previous use of topical estrogen therapy within the last 6 months 4. Has used vaginal creams, moisturizers, lubricants or homeopathic preparations, or received anticoagulants, antiplatelet, thrombolytic, vitamin E or anti-inflammatory within 2 weeks of treatment 5. Has history of heart failure 6. Has equal to or greater than stage III prolapse, according to pelvic organ prolapse quantification system (POP-Q) 7. Has an active sexually transmitted infection (STI) 8. Has signs or symptoms of vulvitis/vaginitis 9. Has signs or symptoms of acute urinary tract infection (UTI) 10. Has participated in any clinical trial involving an investigational drug or procedure within past 30 days 11. The investigator feels that for any reason the subject is not eligible to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03647189

Layout table for location contacts
Contact: Sciton Inc 6504939155

Layout table for location information
United States, Florida
Miamim Dermatology Recruiting
Miami, Florida, United States, 33173
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Sciton Identifier: NCT03647189    
Other Study ID Numbers: DIVA-001
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: December 4, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathological Conditions, Anatomical
Sexual Dysfunction, Physiological
Genital Diseases, Male
Genital Diseases, Female
Sexual Dysfunctions, Psychological
Mental Disorders